F-group (family)
5054.1.1.9 PKD_channel
Ligands and drugs
254
Member domains
101
with ligand contacts (≤ 4 Å)
39.8% of members
86
with DrugDomain annotations
33.9% of members
32
with a DrugBank compound
12.6% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 5054.1.1.9 belongs to X-group 5054 Voltage-gated ion channels, which binds 10.4 ligand superclasses per 20 proteins, broader than 97% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB00141 | NAG | N-Acetylglucosamine | 28 |
| DB02686 | UMQ | Undecyl-Beta-D-Maltopyranoside | 8 |
| DB03796 | PLM | Palmitic Acid | 8 |
| DB04540 | CLR | Cholesterol | 8 |
| DB06287 | A4I | Temsirolimus | 4 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| CAmetal | CALCIUM ION | 31 |
| NAmetal | SODIUM ION | 20 |
| NAG | 2-acetamido-2-deoxy-beta-D-glucopyranose | 18 |
| AQV | 2-{2-oxo-2-[(4S)-2,2,4-trimethyl-3,4-dihydroquinolin-1(2H)-yl]ethyl}-1H-isoindole-1,3(2H)-dione | 16 |
| EUJ | (2R)-3-{[(S)-hydroxy{[(1S,2R,3R,4S,5S,6R)-2,4,6-trihydroxy-3,5-bis(phosphonooxy)cyclohexyl]oxy}phosphoryl]oxy}propane-1,2-diyl dioctanoate | 12 |
| 3PE | 1,2-Distearoyl-sn-glycerophosphoethanolamine | 8 |
| CHS | 4-AMINO-5-CYCLOHEXYL-3-HYDROXY-PENTANOIC ACID | 8 |
| CLR | CHOLESTEROL | 8 |
| HZ7 | (1R,2S,3S,4R,5S,6R)-5-{[(R)-[(2R)-2,3-bis{[(1S)-1-hydroxyoctyl]oxy}propoxy](hydroxy)phosphoryl]oxy}-2,4,6-trihydroxycyclohexane-1,3-diyl bis[dihydrogen (phosphate)] | 8 |
| PIO | [(2R)-2-octanoyloxy-3-[oxidanyl-[(1R,2R,3S,4R,5R,6S)-2,3,6-tris(oxidanyl)-4,5-diphosphonooxy-cyclohexyl]oxy-phosphoryl]oxy-propyl] octanoate | 8 |
| PLM | PALMITIC ACID | 8 |
| PX6 | 1,2-DIPALMITOYL-SN-GLYCERO-3-PHOSPHATE | 8 |
| UMQ | UNDECYL-MALTOSIDE | 8 |
| A1IVC | N4-(3-chloranyl-2-piperidin-1-yl-phenyl)-N1,N1-dimethyl-benzene-1,4-disulfonamide | 4 |
| A4I | (1R,2R,4S)-4-{(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,30S,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontin-3-yl]propyl}-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate | 4 |
| FO4 | sphingomyelin | 4 |
| PEF | DI-PALMITOYL-3-SN-PHOSPHATIDYLETHANOLAMINE | 4 |
| Y01 | CHOLESTEROL HEMISUCCINATE | 4 |
| ZB4 | N-{(1S,2S)-2-[4-(2-methoxyphenyl)piperazin-1-yl]cyclohexyl}benzenesulfonamide | 4 |
| A1EQ3 | (3~{S},7~{R},8~{S},9~{S},10~{R},13~{R},14~{S},17~{R})-10,13-dimethyl-17-[(2~{R},6~{R})-6-methyl-7-oxidanyl-heptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1~{H}-cyclopenta[a]phenanthrene-3,7-diol | 2 |